Lung cancer screening with low dose CT requires careful consideration
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Lung cancer screening with low dose CT requires careful consideration. / Saghir, Zaigham; Ashraf, Haseem; Bach, Karen Skjøldstrup; Brodersen, John; Clementsen, Paul Frost; Døssing, Martin; Hansen, Hanne; Kofoed, Klaus Fuglsang; Larsen, Klaus Richter; Mortensen, Jann; Rasmussen, Jakob Fraes; Thomsen, Laura Hohwü; Wille, Mathilde Marie Winkler; Seersholm, Niels; Skov, Birgit Guldhammer; Thorsen, Hanne; Tønnesen, Philip; Pedersen, Jesper Holst.
I: Ugeskrift for Laeger, Bind 176, Nr. 42, 13.10.2014.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Lung cancer screening with low dose CT requires careful consideration
AU - Saghir, Zaigham
AU - Ashraf, Haseem
AU - Bach, Karen Skjøldstrup
AU - Brodersen, John
AU - Clementsen, Paul Frost
AU - Døssing, Martin
AU - Hansen, Hanne
AU - Kofoed, Klaus Fuglsang
AU - Larsen, Klaus Richter
AU - Mortensen, Jann
AU - Rasmussen, Jakob Fraes
AU - Thomsen, Laura Hohwü
AU - Wille, Mathilde Marie Winkler
AU - Seersholm, Niels
AU - Skov, Birgit Guldhammer
AU - Thorsen, Hanne
AU - Tønnesen, Philip
AU - Pedersen, Jesper Holst
PY - 2014/10/13
Y1 - 2014/10/13
N2 - Results from the American National Lung Screening Trial (NLST) show a significant reduction in lung cancer and all-cause mortality in a high risk population screened with annual low-dose CT. Handling of pulmonary nodules, false positive tests, overdiagnosis, psychosocial consequences and cost-efficiency etc. are all aspects that require careful consideration. This paper gives an overview of the current knowledge on these issues. Before a recommendation can be made, we need an overall evaluation of both the benefits and harms in CT screening for lung cancer.
AB - Results from the American National Lung Screening Trial (NLST) show a significant reduction in lung cancer and all-cause mortality in a high risk population screened with annual low-dose CT. Handling of pulmonary nodules, false positive tests, overdiagnosis, psychosocial consequences and cost-efficiency etc. are all aspects that require careful consideration. This paper gives an overview of the current knowledge on these issues. Before a recommendation can be made, we need an overall evaluation of both the benefits and harms in CT screening for lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=85040648298&partnerID=8YFLogxK
M3 - Review
C2 - 25316363
AN - SCOPUS:85040648298
VL - 176
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 42
ER -
ID: 221821709